Table 2.

Secondary end points on the basis of the available patients at the end of the trial phase: high-GFR arm

End Point	Supportive Care, n=54		Corticosteroid Monotherapy, n=55		P Value
	Patients with Available Data, No.	End Point Value, Mean±SD or No. (%)	Patients with Available Data, No.	End Point Value, Mean±SD or No. (%)
GFR decrease ≥30 ml/min per 1.73 m2	52	6 (12)	53	5 (9)	0.68
Onset of ESRD	52	5 (10)	53	1 (2)	0.16
Disappearance of microhematuria	38a	7 (18)	40a	19 (48)	0.02
Absolute GFR changes at month 36, ml/min per 1.73 m2	48	−3.78±13.41	52	−4.07±15.66	0.98
Mean annual change in the slope of the reciprocal of serum creatinine concentration, mg/dl	53	−0.02±0.06	52	−0.01±0.06	0.35
Urinary protein-to-creatinine ratio at month 12, g/g	47	0.79±0.74	41	0.5±0.52	0.01
Urinary protein-to-creatinine ratio at month 36, g/g	46	0.80±0.64	43	0.57±0.53	0.26

^aA total of 45 patients in the supportive care group and 50 patients in the corticosteroid monotherapy group had microhematuria at baseline.